Clinical trial
Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients…
NCT00499577 · University of Maryland Greenebaum Cancer Center, Other · Completed
Key facts
| NCT number | NCT00499577 |
|---|---|
| Title | Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma |
| Official title | Phase I/II Combination Immunotherapy After ASCT for Advanced Myeloma to Study HTERT Vaccination Followed by Adoptive Transfer of Vaccine-Primed Autologous T Cells |
| Lead sponsor | University of Maryland Greenebaum Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Biological |
| Interventions | CMV pp65 peptide, hTERT I540/R572Y/D988Y multipeptide vaccine, pneumococcal polyvalent vaccine, survivin Sur1M2 peptide vaccine |
| Enrollment | 56 |
| Start date | Dec 1, 2006 |
| Primary completion | Feb 1, 2009 |
| First posted | Jul 11, 2007 |
| Last update posted | Jan 10, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: